Skip to Main Content

Paper Details

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
Clin Cancer Res
6
2022
B1B2P2, BRCA, BRCA tumors, BRCA-related cancers, BRCA1, BRCA1/2, BRCA2, CGT, P, PALB2, Patients, Tumor, breast, pancreatic, prostate, ovarian, nonmelanoma skin, endometrial, small cell lung, and colorectal cancers, cancer, cancer predisposition genes, familial cancer, malignancies, non-, non-BRCA tumors, patients, tumor
Author NameAffiliation
Matthew B YurgelunDana-Farber Cancer Institute
Matthew B YurgelunDana-Farber Cancer Institute
Matthew B YurgelunHarvard Medical School
Mary-Ellen TaplinDana-Farber Cancer Institute
Mary-Ellen TaplinHarvard Medical School
Laura E MacConaillHarvard Medical School
Laura E MacConaillBrigham and Women's Hospital
Laura E MacConaillCenter for Cancer Genomics, Dana-Farber Cancer Institute
Judy E GarberDana-Farber Cancer Institute
Judy E GarberDana-Farber Cancer Institute
Judy E GarberHarvard Medical School
Nancy U LinDana-Farber Cancer Institute
Nancy U LinHarvard Medical School
  • 1 - 13

Datasets

Release 1.2